XVIPF
Xvivo Perfusion AB (publ)
OTC Markets OTCPKUSDEQUITY
DELAYED
Last price
30.95
■ 0.00 (0.00%)
MARKET · —
Price
Chart style
Interval
Intraday intervals only cover recent history. The site picks the finest interval the range allows.
Overlays
Session levels
Lower pane
Overlay another symbol
Both series are rebased to 0% at the left edge, so the lines show relative performance rather than price.
Tool
1D
—
H —
L —
Range —
Vol —
vs
Drag pan · Pinch zoom · Hold crosshair · pick a tool then drag to draw
Open
—
Prev close
30.95
Day high
30.95
Day low
30.95
Volume
100
Market cap
—
P/E (TTM)
—
52W range
16.98 – 30.95
Trailing performance
Returnvs SPY
1W
+26.33%
+27.5%
1M
+26.33%
+23.0%
3M
+5.31%
+2.9%
6M
+31.59%
+19.7%
YTD
+49.52%
+37.6%
1Y
+50.71%
+30.6%
3Y
+10.73%
-64.2%
5Y
—
—
Price return only. Dividends are not reinvested, so total return on a dividend payer will be higher than shown.
Free account
6 more panels on XVIPF open with an account.
Options chains and analytics, valuation ratios, insider filings, analyst targets and ownership. No card, no trial, nothing to cancel.
Fundamentals
Market cap—
Enterprise value—
Revenue (TTM)—
Gross profit—
EBITDA—
Net income—
EPS (TTM)—
Free cash flow—
Total cash—
Total debt—
Book value / share—
Shares outstanding—
Float—
Short % of float—
Dividend yield—
Beta (5Y)—
Valuation & profitability ratios
Trailing P/E—
Forward P/E—
PEG ratio—
Price / sales—
Price / book—
EV / revenue—
EV / EBITDA—
Gross margin—
Operating margin—
Profit margin—
Return on equity—
Return on assets—
Debt / equity—
Current ratio—
Fourteen ratios including P/E, PEG, EV/EBITDA, margins and return on equity.
Financial statements
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Total revenue | $812.16M | $822.41M | $597.54M | $415.29M | -1.2% |
| Operating revenue | $812.16M | $822.41M | $597.54M | $415.29M | -1.2% |
| Cost of revenue | $212.67M | $206.00M | $152.43M | $118.34M | +3.2% |
| Gross profit | $599.49M | $616.41M | $445.11M | $296.96M | -2.7% |
| Research & development | $131.99M | $148.33M | $135.94M | $69.34M | -11.0% |
| Selling, general & admin | $377.09M | $379.77M | $309.20M | $223.38M | -0.7% |
| Total operating expense | $507.37M | $527.01M | $439.71M | $292.50M | -3.7% |
| Operating income | $92.12M | $89.41M | $5.40M | $4.46M | +3.0% |
| Net interest income | $16.78M | $78.93M | $80.44M | $1.03M | -78.7% |
| Pre-tax income | $38.56M | $199.95M | $94.52M | $22.31M | -80.7% |
| Tax provision | $13.40M | $27.77M | $2.70M | $3.89M | -51.7% |
| Net income | $25.16M | $172.18M | $91.82M | $18.43M | -85.4% |
| Net income to common | $25.16M | $172.18M | $91.82M | $18.43M | -85.4% |
| Basic EPS | 0.80 | 5.47 | 3.07 | 0.62 | -85.4% |
| Diluted EPS | 0.80 | 5.44 | 3.07 | 0.62 | -85.3% |
| EBIT | $42.04M | $201.21M | $95.71M | $22.92M | -79.1% |
| EBITDA | $112.25M | $288.92M | $172.06M | $65.09M | -61.1% |
| Basic shares | 31.50M | 31.50M | 29.94M | 29.53M | 0.0% |
| Diluted shares | 31.56M | 31.65M | 29.94M | 29.53M | -0.3% |
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Cash & equivalents | $292.09M | $415.52M | $546.09M | $246.25M | -29.7% |
| Cash & short-term investments | $292.09M | $415.52M | $546.09M | $246.25M | -29.7% |
| Accounts receivable | $101.34M | $117.29M | $98.13M | $94.50M | -13.6% |
| Inventory | $248.46M | $227.41M | $141.60M | $106.57M | +9.3% |
| Total current assets | $688.21M | $813.08M | $826.40M | $467.51M | -15.4% |
| Property, plant & equipment | $213.88M | $149.04M | $97.55M | $47.58M | +43.5% |
| Goodwill & intangibles | $1.45B | $1.41B | $1.22B | $1.18B | +3.1% |
| Total assets | $2.37B | $2.40B | $2.20B | $1.73B | -1.2% |
| Total current liabilities | $119.38M | $177.51M | $134.49M | $134.90M | -32.7% |
| Total debt | $124.72M | $34.04M | $31.44M | $10.01M | +266.4% |
| Total liabilities | $260.65M | $245.97M | $250.57M | $302.95M | +6.0% |
| Retained earnings | $316.90M | $291.76M | $119.57M | $27.75M | +8.6% |
| Shareholder equity | $2.11B | $2.16B | $1.95B | $1.43B | -2.0% |
| Working capital | $568.83M | $635.57M | $691.92M | $332.61M | -10.5% |
| Net tangible assets | $663.11M | $749.50M | $724.69M | $251.82M | -11.5% |
| Shares issued | 31.50M | 31.50M | 31.50M | 29.83M | 0.0% |
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Net income | $38.56M | $199.95M | $94.52M | $22.31M | -80.7% |
| Depreciation & amortisation | $70.21M | $87.72M | $76.35M | $42.17M | -20.0% |
| Stock-based compensation | $14.41M | $6.57M | $2.30M | $0 | +119.3% |
| Change in working capital | -$68.73M | -$79.11M | -$39.22M | -$22.17M | +13.1% |
| Operating cash flow | $101.07M | $111.29M | $46.29M | $27.86M | -9.2% |
| Capital expenditure | -$252.91M | -$193.15M | -$143.94M | -$130.95M | -30.9% |
| Investing cash flow | -$258.41M | -$243.81M | -$161.62M | -$197.62M | -6.0% |
| Share buybacks | — | — | — | -$368.00K | — |
| Financing cash flow | $72.25M | -$10.90M | $418.55M | -$6.84M | +762.7% |
| Free cash flow | -$151.84M | -$81.86M | -$97.65M | -$103.09M | -85.5% |
| End cash position | $292.09M | $415.52M | $546.09M | $246.54M | -29.7% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-06-30 | 2025-03-31 | YoY |
|---|---|---|---|---|---|---|
| Total revenue | $238.99M | $240.96M | $226.14M | $178.29M | $218.59M | -0.8% |
| Operating revenue | $238.99M | $240.96M | $226.14M | $178.29M | $218.59M | -0.8% |
| Cost of revenue | $69.49M | $69.92M | $62.07M | $45.64M | $58.21M | -0.6% |
| Gross profit | $169.50M | $171.04M | $164.08M | $132.66M | $160.37M | -0.9% |
| Research & development | $36.08M | $36.78M | $33.16M | $31.90M | $35.48M | -1.9% |
| Selling, general & admin | $111.39M | $102.89M | $93.81M | $94.24M | $96.73M | +8.3% |
| Total operating expense | $144.51M | $139.09M | $127.26M | $125.57M | $133.81M | +3.9% |
| Operating income | $24.99M | $31.94M | $36.82M | $7.08M | $26.57M | -21.8% |
| Net interest income | $7.74M | $10.88M | $4.37M | -$10.43M | -$40.62M | -28.8% |
| Pre-tax income | $32.73M | $42.83M | $41.19M | -$3.34M | -$14.05M | -23.6% |
| Tax provision | $16.45M | $6.53M | $9.54M | -$4.92M | -$1.65M | +152.0% |
| Net income | $16.28M | $36.30M | $31.65M | $1.57M | -$12.40M | -55.1% |
| Net income to common | $16.28M | $36.30M | $31.65M | $1.57M | -$12.40M | -55.1% |
| Basic EPS | 0.52 | 1.15 | 1.01 | 0.05 | -0.39 | -54.8% |
| Diluted EPS | 0.52 | 1.15 | 1.01 | 0.05 | -0.39 | -54.8% |
| EBIT | $24.99M | $31.94M | $36.82M | $7.08M | $26.57M | -21.8% |
| EBITDA | $24.99M | $31.94M | $36.82M | $7.08M | $26.57M | -21.8% |
| Basic shares | 31.50M | 31.50M | 31.50M | 31.50M | 31.50M | 0.0% |
| Diluted shares | 31.52M | 31.56M | 31.56M | 31.56M | 31.65M | -0.1% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-06-30 | 2025-03-31 | YoY |
|---|---|---|---|---|---|---|
| Cash & equivalents | $304.96M | $308.14M | $292.09M | $323.00M | $315.87M | -1.0% |
| Cash & short-term investments | $304.96M | $308.14M | $292.09M | $323.00M | $315.87M | -1.0% |
| Accounts receivable | $196.02M | $189.33M | $101.34M | $180.90M | $184.67M | +3.5% |
| Inventory | $227.87M | $227.22M | $248.46M | $269.38M | $225.88M | +0.3% |
| Total current assets | $728.86M | $724.69M | $688.21M | $773.28M | $726.42M | +0.6% |
| Property, plant & equipment | $218.28M | $215.16M | $213.88M | $177.85M | $151.81M | +1.5% |
| Goodwill & intangibles | $1.56B | $1.50B | $1.45B | $1.41B | $1.38B | +3.9% |
| Total assets | $2.53B | $2.47B | $2.37B | $2.39B | $2.30B | +2.3% |
| Total current liabilities | $188.83M | $160.36M | $119.38M | $160.79M | $139.63M | +17.8% |
| Total debt | $121.62M | $122.68M | $124.72M | $110.81M | $29.31M | -0.9% |
| Total liabilities | $326.64M | $299.60M | $260.65M | $295.46M | $202.68M | +9.0% |
| Retained earnings | $369.49M | $353.20M | $316.90M | $280.92M | $279.36M | +4.6% |
| Shareholder equity | $2.20B | $2.17B | $2.11B | $2.09B | $2.09B | +1.4% |
| Working capital | $540.02M | $564.32M | $568.83M | $612.49M | $586.79M | -4.3% |
| Net tangible assets | $639.61M | $667.41M | $663.11M | $685.23M | $708.20M | -4.2% |
| Shares issued | 31.50M | 31.50M | 31.50M | 31.50M | 31.50M | 0.0% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-06-30 | 2025-03-31 | YoY |
|---|---|---|---|---|---|---|
| Net income | $32.73M | $42.83M | $41.19M | -$3.34M | -$14.05M | -23.6% |
| Change in working capital | $13.85M | $12.16M | $18.33M | -$11.39M | -$60.20M | +13.9% |
| Operating cash flow | $63.49M | $65.34M | $86.93M | $8.80M | -$15.25M | -2.8% |
| Investing cash flow | -$67.60M | -$54.67M | -$66.47M | -$72.38M | -$58.94M | -23.6% |
| Financing cash flow | -$2.71M | -$3.12M | -$2.55M | $81.56M | -$3.00M | +13.2% |
| Free cash flow | $63.49M | $65.34M | $86.93M | $8.80M | -$15.25M | -2.8% |
| End cash position | $304.96M | $308.14M | $292.09M | $323.00M | $315.87M | -1.0% |
Analyst targets & ownership
Mean target—
High target—
Low target—
Implied upside—
Analyst count—
Consensus—
Strong buy / Buy— / —
Hold—
Sell / Strong sell— / —
Held by insiders—
Held by institutions—
Institutions holding—
Price targets, consensus spread, insider and institutional ownership.
Moving averages & technicals
SMA 10
27.73
+11.63% from price
SMA 20
26.11
+18.53% from price
SMA 50
27.37
+13.10% from price
SMA 100
26.14
+18.40% from price
SMA 200
23.27
+33.03% from price
EMA 12
28.22
+9.69% from price
EMA 26
27.16
+13.95% from price
EMA 50
26.84
+15.32% from price
RSI (14)
86.1
Overbought
MACD (12,26,9)
1.06
Hist 0.90
ATR (14)
0.46
1.49% of price
Realised vol 30D
78.6%
Annualised
Bollinger upper
31.70
20, 2σ
Bollinger lower
20.53
20, 2σ
50 / 200 cross
Golden
27.37 vs 23.27
Trend bias
Above 200
+33.03%
Options chain
Calls
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Puts
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Every listed expiry, both sides of the book, with volume, open interest and implied volatility.
Risk profile
Beta vs SPY
0.27
Less volatile than market
Correlation to SPY
0.06
Largely independent
Realised vol 30D
78.6%
Annualised
Market vol 1Y
12.8%
SPY, annualised
Max drawdown 1Y
-24.9%
Peak to trough
Max drawdown 5Y
-78.3%
Peak to trough
ATR 14
0.46
1.49% of price
Beta (reported)
—
5Y monthly, from filing
Headlines
XVIVO Receives CE Certificates for Its Groundbreaking Heart Preservation Technology, Transforming Access to Life-Saving Transplants Across Europe
ACCESS Newswire · 13d ago
XVIVO Granted Additional Patient Enrollment in the US PRESERVE CAP Study for XVIVO Heart Assist Transport
ACCESS Newswire · 21d ago
Xvivo Perfusion AB (XVIPF) Q2 2026 Earnings Call Highlights: Strong Organic Growth Amidst ...
GuruFocus.com · 41d ago
Interim Report January - June 2026
ACCESS Newswire · 42d ago
Conference call on Interim Report April-June 2026
ACCESS Newswire · 59d ago
Exploring European Undervalued Small Caps With Insider Action In June 2026
Simply Wall St. · 75d ago
PRIVATE STRATEGY · BY QUALIFICATION
The same data. A different seat.
The research you are reading is the input layer for a discretionary options program we run for a small number of qualified investors. Minimum $1,000,000.